Credence Research Logo

Home » Healthcare » Pharmaceuticals » Nosocomial Infection Treatment Market

Nosocomial Infection Treatment Market By Type of infection (Urinary Tract Infections (UTIs), Surgical Site Infections (SSIs), Pneumonia, Bloodstream Infections, Gastrointestinal Infections, Skin and Soft Tissue Infections) By Treatment Type (Antibiotics, Antifungal Agents, Antiviral Drugs, Surgical Interventions, Supportive Care) By End User (Hospitals, Long-Term Care Facilities, Ambulatory Surgical Centers, Clinics and Outpatient Settings, Home Healthcare) By Infection (Ventilator Associated Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Gastrointestinal Infection, MRSA), By Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4699

Published: | Report ID: 14189 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period 2019-2022
Base Year 2023
Forecast Period 2024-2032
Nosocomial Infection Treatment Market Size 2023 USD 30154.56 Million
Nosocomial Infection Treatment Market, CAGR 1.90%
Nosocomial Infection Treatment Market Size 2032 USD 35720.76 Million

Market Insights

  • The global demand for nosocomial infection treatment was valued at USD 30154.56 Million in 2023 and is expected to reach USD 35720.76 Million in 2032, growing at a CAGR of 1.90% between 2024 and 2032.
  • Urinary Tract Infections (UTIs) are the market leader by type of infection, accounting for a significant portion of total value in 2023, while the bloodstream infections segment is expected to grow rapidly throughout the forecast period.
  • Antibiotics segment dominates the global market by treatment type, accounting for a significant portion in 2023. The antifungal agent segment is predicted to expand at a high CAGR.
  • Over the projection period, long-term care facilities are expected to expand at the highest rate, while hospitals dominate the market in 2023 with a substantial share.
  • North America is dominating the Nosocomial Infection Treatment industry with a substantial share in 2023, while Asia Pacific is expected to grow at the highest rate during the forecast period.
  • The market’s primary possibilities include advancements in medical technology, increased awareness of infection prevention measures, and innovative therapeutic approaches.

Executive Summary

Market Definition

Nosocomial infections, also known as hospital-acquired infections (HAIs), are infections that patients acquire during their stay in healthcare facilities, such as hospitals or nursing homes. These infections can arise from various factors, including surgical procedures, catheter use, and exposure to contaminated equipment or environments.

Treatments for nosocomial infections involve targeted antibiotic or antifungal therapies, chosen based on the specific pathogen responsible for the infection. In addition, supportive care measures such as wound care, intravenous fluids, and oxygen can be adopted. Implementing strict infection control measures, including adherence to hygiene protocols, proper sterilization of medical instruments, and isolating infected patients, is essential in both the prevention and management of these infections.

The goal of nosocomial infection treatment is to reduce the incidence and impact of healthcare-associated infections, thereby improving patient outcomes and ensuring the safety of both patients and healthcare workers.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Overview

The global nosocomial infection treatment market has witnessed steady growth in recent years and is expected to grow at a CAGR of 1.90% between 2024 and 2032. The market was valued at USD 30154.56 million in 2023 and is expected to reach USD 35720.76 million in 2032.

The global Nosocomial Infection Treatment market is experiencing robust growth, driven primarily by the rising incidence of hospital-acquired infections. As healthcare systems globally advance, the use of invasive procedures and medical devices such as catheters, surgical implants, and ventilators has become more prevalent. These devices, while indispensable for modern medical care, increase the risk of infections, particularly in settings where maintaining stringent hygiene protocols is challenging.

Moreover, the rising aging population is substantially driving the demand for nosocomial infection treatment. Older adults are more vulnerable to infections due to a natural decline in immune function and the higher likelihood of chronic conditions necessitating frequent and prolonged hospital stays. This demographic shift has led to an increase in elderly patients requiring medical interventions, thereby escalating the occurrence of nosocomial infections.

Additionally, the growing prevalence of chronic diseases such as diabetes, cancer, and respiratory illnesses, which often require continuous medical care, further heightens the risk of hospital-acquired infections. Furthermore, technological advancements in diagnostics and therapeutic interventions are also fueling the market. Innovations in rapid diagnostic tools allow for the swift identification of pathogens, enabling timely and targeted treatment essential for managing nosocomial infections effectively.

In addition, the development of advanced antimicrobial therapies, including novel antibiotics, antifungals, and antiviral medications, is enhancing treatment outcomes. The introduction of infection control products such as antimicrobial-coated medical devices and advanced disinfectants further supports the effective management and prevention of these infections.

The increasing emphasis on stringent infection control protocols and the expansion of healthcare infrastructure in emerging economies contribute to market growth. Governments and healthcare organizations worldwide are prioritizing the implementation of robust infection prevention and control measures. Regulatory initiatives aimed at reducing hospital-acquired infections are leading to higher investments in infection control products and treatment solutions. These factors collectively highlight the urgent need for effective infection control and treatment strategies, driving the ongoing expansion of this market.

Segmentation by Type of Infection

  • Urinary Tract Infections (UTIs) are the leading segment by type of infection and hold a substantial share in 2023. This dominance is due to their high incidence rates in hospital settings, particularly among catheterized patients. UTIs are the most common type of hospital-acquired infections, significantly impacting patient morbidity and healthcare costs. Hospitals implement rigorous protocols for prevention and management, but the high prevalence still drives substantial demand for treatment options.
  • Bloodstream infections are expected to grow at the highest CAGR during the projected period. This growth is driven by the increasing occurrence of sepsis and central line-associated bloodstream infections (CLABSIs) in intensive care units. Advances in diagnostic technologies and the development of novel antimicrobial therapies are further propelling the growth in this segment. The critical nature of bloodstream infections, requiring immediate and effective treatment, underscores the rapid expansion of this market segment.
  • Other segments, such as surgical site infections (SSIS), pneumonia, gastrointestinal infections, and skin & soft tissue infections, also contribute substantially to the market share.

Segmentation by Treatment Type

  • The antibiotics segment boasts the dominating position in the nosocomial infection treatment industry, holding a massive share in 2023. This dominance is primarily due to their widespread use as the first line of defense against bacterial infections, which are the most common type of nosocomial infections. Antibiotics are essential for treating a variety of infections, such as urinary tract infections (UTIs), bloodstream infections, and pneumonia, which are prevalent in hospital settings. The broad-spectrum efficacy and critical role of antibiotics in immediate and effective infection management contribute to their significant market share.
  • The Antifungal Agents segment is expected to grow at the highest CAGR during the projected period. The rapid growth of this segment can be attributed to the increasing incidence of fungal infections in hospital settings, especially among immunocompromised patients, including those undergoing chemotherapy, organ transplants, or those with HIV/AIDS. Antifungal treatments are becoming more critical as the rise in invasive fungal infections requires effective and specialized treatment options. Additionally, the development of new antifungal drugs and the rising awareness of fungal infections are propelling the growth of this segment.
  • Other treatment types, including antiviral drugs, surgical interventions, and supportive care, further contribute significantly to the market’s growth.

Segmentation by End-User

  • Hospitals boast the dominating position in the nosocomial infection treatment industry, holding a massive share in 2023. This is due to the high incidence of nosocomial infections within hospital settings, where patients are at a higher risk of contracting infections due to prolonged stays, surgeries, and invasive procedures. Hospitals require extensive treatment protocols and a variety of medications and interventions to manage these infections effectively, leading to a larger demand for nosocomial infection treatments in these facilities.
  • Long-term care facilities are expected to grow at the highest rate during the forecasted period. The growth in this segment can be attributed to the increasing elderly population, who are more susceptible to infections and often require extended stays in such facilities. Due to the close living quarters and the compromised health status of the residents, long-term care facilities are witnessing a rise in nosocomial infections. This has driven the demand for effective infection control measures and treatments, thereby propelling the growth of this market segment.
  • Ambulatory Surgical Centers, Clinics and Outpatient Settings, and Home Healthcare segments contribute significantly to the growth of the market.

Segmentation by Region

  • North America dominates the Nosocomial Infection Treatment industry with a massive share in 2023 due to the increase in hospital stays due to chronic diseases and surgeries, coupled with innovative technologies implemented in devices that control infections.
  • The Asia Pacific market is expected to grow at the highest rate during the forecasted period.
  • The rest of the world, including Latin America, the Middle East, and Africa, supplies the remaining demand for the Nosocomial Infection Treatment industry.

North America holds a significant market share in the nosocomial infections treatment market owing to the increase in hospital stays due to chronic diseases and surgeries, coupled with innovative technologies implemented in devices that control infections. In American hospitals alone, the Centers for Disease Control (CDC) estimates that healthcare-associated infections (HAIs) account for approximately 1.7 million infections and 99,000 associated deaths each year. This high incidence highlights the critical need for effective infection control measures and treatments, propelling market growth.

Additionally, the rise in chronic diseases such as cardiovascular diseases and cancer requires extended hospital stays and frequent surgical interventions. According to 2022 data from the American Health Association, there were approximately 33 million hospital admissions in the U.S., highlighting the substantial demand for infection control solutions. The increased number of hospital admissions and longer patient stays elevate the risk of nosocomial infections, further driving the need for advanced treatment options.

Moreover, Innovative technological advancements also play a crucial role in market growth. For example, in February 2021, Penn Medicine opened its new Interventional Support Center (ISC) in Southwest Philadelphia, one of the largest instrument processing and surgical supply preparation facilities in the region. The ISC is among the first facilities of its kind in Pennsylvania, where staff sterilize and package thousands of instruments daily in preparation for surgeries and procedures, from basic scissors and clamps to advanced robotic instruments. The establishment of such state-of-the-art facilities is expected to enhance infection control practices and drive the growth of the nosocomial infection treatment market in North America.

On the other hand, the Asia-Pacific region is poised for significant growth in the nosocomial infections treatment market due to the region’s rapidly aging population. With the Asia-Pacific population aging at a faster rate than any other region globally, according to projections from the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the prevalence of nosocomial infections is expected to rise significantly. This demographic shift results in a higher susceptibility to infections among the elderly, who often require prolonged hospital stays and have weakened immune systems, necessitating specialized treatment and prevention measures.

Moreover, governments in the Asia Pacific are making substantial investments in healthcare infrastructure to meet the evolving healthcare needs of their populations. For instance, initiatives such as India’s establishment of infectious disease (ID) blocks in district hospitals (DHs) and the implementation of the National Action Plan (NAP) to combat antimicrobial resistance (AMR) underscore a concerted effort to enhance healthcare facilities and services. These investments are crucial for improving access to quality healthcare and necessitate advanced infection treatment methods to maintain hygiene standards and mitigate the risk of nosocomial infections.

Additionally, international collaborations and support play a vital role in addressing nosocomial infections in the Asia Pacific region. Partnerships between local healthcare authorities and international organizations, such as the collaboration between the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), and the Centers for Disease Control and Prevention (CDC) of the USA, bring in technical expertise and financial support to strengthen infection prevention and control measures. These collaborations are particularly crucial in intensive care units (ICUs) of tertiary care hospitals, where the risk of nosocomial infections is high. The involvement of global health entities such as the World Health Organization (WHO) underscores the importance of addressing nosocomial infections in low- and middle-income countries, highlighting the market growth prospects in the Asia-Pacific region.

Key Highlights of the Report

The global Nosocomial Infection Treatment Market is segmented by type of infection, treatment type, end-user, and region. Antibiotics are the most popular segment, while urinary tract infections (UTIs) are the primary type of infection. In addition, Hospitals are the most demanding end-users, with the North American region leading the market share.

The nosocomial infections treatment market is growing due to the rising incidence of hospital-acquired infections, driven by the increased use of invasive procedures and medical devices. The growing geriatric population is more susceptible to infections due to weakened immune systems and chronic illnesses, leading to the growth of the market. Additionally, heightened awareness and stringent infection control regulations are leading to greater investments in infection prevention. Expanding healthcare infrastructure in emerging economies further boosts the demand for effective nosocomial infection treatments.

Nonetheless, North America is anticipated to have the greatest share of the worldwide nosocomial infection treatment market owing to the increase in hospital stays due to chronic diseases and surgeries, coupled with innovative technologies implemented in devices that control infections. Furthermore, the market is anticipated to expand at the highest rate in the Asia-Pacific region due to the region’s rapidly aging population, substantial investments in healthcare infrastructure to meet evolving healthcare needs, and partnerships between local healthcare authorities and international organizations.

What Are the Main Drivers of the Global Nosocomial Infection Treatment Market?

The nosocomial infection treatment market is expanding due to the increasing incidence of hospital-acquired infections fueled by the greater use of invasive procedures and medical devices. The aging population, more prone to infections because of weakened immune systems and chronic diseases, also drives the market growth. Additionally, heightened awareness and stringent infection control regulations are prompting more investments in infection prevention. The expanding healthcare infrastructure in emerging economies further amplifies the demand for effective nosocomial infection treatments.

What Are the Major Challenges Faced by the Global Nosocomial Infection Treatment Market?

The nosocomial infection treatment market is expanding due to the increasing incidence of hospital-acquired infections fueled by the greater use of invasive procedures and medical devices. The aging population, more prone to infections because of weakened immune systems and chronic diseases, also drives the market growth. Additionally, heightened awareness and stringent infection control regulations are prompting more investments in infection prevention. The expanding healthcare infrastructure in emerging economies further amplifies the demand for effective nosocomial infection treatments.

What Are the Growth Opportunities in the Global Nosocomial Infection Treatment Market?

Technological advancements in healthcare are creating substantial opportunities for the growth of the nosocomial infection treatment market. Innovations in diagnostic tools and therapeutic interventions are revolutionizing infection control and treatment, leading to more efficient and effective healthcare solutions. Rapid diagnostic technologies, such as PCR and next-generation sequencing, enable quicker and more accurate pathogen identification. This allows for timely and targeted treatments, reducing infection spread and improving patient outcomes. These advancements are transforming healthcare systems, leading to better patient care and robust healthcare infrastructures in the future.

Market Drivers

Growing incidence of various types of hospital-acquired infections (HAIs).

A significant factor driving the growth of the nosocomial infections treatment market is the rising incidence of various types of hospital-acquired infections (HAIs). According to the Centers for Disease Control and Prevention (CDC), catheter-associated urinary tract infections (CAUTIs) are among the most common types of healthcare-associated infections. Approximately 75% of urinary tract infections (UTIs) developed in hospitals are linked to the use of urinary catheters, with 15-25% of hospitalized patients requiring these devices. CAUTIs contribute to increased morbidity, mortality, healthcare costs, and extended hospital stays, underscoring the need for effective treatment and prevention strategies.

Additionally, a 2022 report from the World Health Organization (WHO) highlights the global burden of HAIs. It reveals that out of every 100 patients in acute-care hospitals, seven patients in high-income countries and 15 patients in low- and middle-income countries acquire at least one healthcare-associated infection during their hospital stay. Alarmingly, on average, one in every ten affected patients will die from their HAI. The impact of HAIs and antimicrobial resistance on patient outcomes is profound, with over 24% of patients affected by healthcare-associated sepsis and 52.3% of those treated in intensive care units succumbing to these infections annually. The mortality rate increases two to threefold when infections are resistant to antimicrobials, emphasizing the urgent need for advanced treatment options and robust infection control measures.

The escalating prevalence of HAIs, such as CAUTIs, and their severe consequences drive the demand for effective nosocomial infection treatments. The increasing recognition of these infections’ impact on patient health, hospital resources, and healthcare costs is spurring investments in the development and deployment of innovative diagnostic and therapeutic solutions. Enhanced infection control protocols and regulatory frameworks further support this growth as healthcare systems worldwide strive to mitigate the risks and outcomes associated with HAIs. As a result, the nosocomial infections treatment market continues to expand, addressing a critical need in modern healthcare.

Market Restraints

Impact of Antimicrobial Resistance

The growing problem of antimicrobial resistance (AMR) poses a critical challenge, as pathogens responsible for hospital-acquired infections are increasingly resistant to standard treatments. This resistance makes infections harder to treat, leading to longer hospital stays, higher medical costs, and increased mortality. The diminishing efficacy of existing antibiotics necessitates the development of new, more effective drugs, which is a lengthy and costly process.

Additionally, the financial burden associated with developing and implementing advanced diagnostic tools and therapeutic interventions is substantial. While innovative treatments and technologies are effective, they often come with significant price tags, making them less accessible, especially in low- and middle-income countries. The high costs limit the widespread adoption of new treatments and technologies, thereby restraining market growth.

Opportunities

Advancements in Healthcare Technologies

Technological advancements represent a pivotal factor in creating substantial opportunities for the future growth of the nosocomial infection treatment market. Innovations in diagnostic tools and therapeutic interventions are revolutionizing the landscape of infection control and treatment, paving the way for more efficient, accurate, and effective healthcare solutions. Rapid diagnostic technologies are at the forefront of this transformation.

Traditional diagnostic methods, often time-consuming and less precise, are being replaced by advanced techniques that enable the quicker and more accurate identification of pathogens. These modern diagnostics include molecular methods such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and mass spectrometry, which provide high sensitivity and specificity. The ability to rapidly detect and identify specific pathogens allows healthcare providers to initiate timely and targeted treatments, significantly reducing the spread of infections and improving patient outcomes.

Researchers and pharmaceutical companies are exploring innovative alternatives such as bacteriophage therapy, antimicrobial peptides, and nanotechnology-based solutions. Additionally, nanotechnology is being harnessed to develop advanced drug delivery systems and novel antimicrobial agents. Nanoparticles can be engineered to deliver drugs directly to the site of infection, enhancing drug efficacy and reducing side effects.

Furthermore, nanomaterials with intrinsic antimicrobial properties are being explored for use in coatings, wound dressings, and medical devices to prevent infection. The adoption of these advanced technologies is transforming healthcare systems worldwide. Improved diagnostics and novel treatments enhance the ability to manage and control infections, reducing healthcare-associated costs and improving overall patient care, ultimately leading to better patient outcomes and more robust healthcare systems.

Competitive Landscape

Key Players

The global nosocomial infection treatment market is highly competitive, with several key players. Some of the major players in the market are as follows:

  • 3M Company
  • Abbott Laboratories
  • Advanced Sterilization Products Services Inc. (ASP)
  • Becton, Dickinson and Company (BD)
  • Belimed AG
  • BioMérieux SA
  • Cantel Medical Corp.
  • Getinge Group
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Roche Diagnostics Corporation
  • Stryker Corporation
  • Thermo Fisher Scientific Inc.
  • Steris Corporation
  • Zimmer Biomet Holdings, Inc.
  • Ansell Limited
  • Molnlycke Health Care AB
  • Cantel Medical Corp.

These organizations prioritize product launches and business expansion to stay competitive.

The key players in the global nosocomial infection treatment market continually seek to stay ahead by offering new products and developments.

In May 2024, Sanofi announced a significant investment of over €1 billion to enhance its biomanufacturing capabilities in France. This investment aims to bolster the production of essential medicines and vaccines, reinforcing France’s health sovereignty. Part of this investment includes the creation of new bioproduction capacity at Sanofi’s sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland. These efforts are crucial for advancing the production of biologics and vaccines, which are essential in the treatment of nosocomial infections and other critical health conditions.

In December 2023, 3M announced that the company received approval for its Tegaderm CHG Chlorhexidine Gluconate Dressing from the Australian Register of Therapeutic Goods (ARTG). This product, classified as a Class III medical device, represents a significant advancement in the nosocomial infection treatment market. The Tegaderm CHG dressing is designed to secure catheter sites and reduce both skin and catheter colonization, effectively suppressing the growth of microorganisms associated with bloodstream infections (CRBSI). The dressing, featuring an antimicrobial synthetic polymer semi-permeable film and its functional design, allows for the securement of various vascular access devices, contributing to improved patient outcomes and reduced infection rates in clinical settings.

How are Companies Performing in the Nosocomial Infection Treatment Market?

The global nosocomial infection treatment market is highly competitive, with several key players.

Startups are playing a pivotal role in revolutionizing the nosocomial infection treatment industry by introducing innovative solutions to combat hospital-acquired infections. These entrepreneurial ventures are leveraging cutting-edge technology, novel approaches, and interdisciplinary collaborations to address the challenges associated with nosocomial infections. Startups are significantly contributing to the industry through the development of advanced infection prevention and control systems.

These systems utilize artificial intelligence (AI) and machine learning algorithms to analyze data and identify patterns that could indicate potential outbreaks or areas of infection risk within healthcare facilities. For instance, Day Zero Diagnostics is revolutionizing the diagnosis and treatment of hospital-acquired infections by utilizing whole-genome sequencing and machine-learning algorithms to identify pathogens and antibiotic resistance patterns rapidly. Their approach allows for more precise and targeted antibiotic therapy, reducing the risk of treatment failure and the spread of multidrug-resistant bacteria.

Additionally, some startups are focusing on improving hand hygiene practices among healthcare workers, which is critical for preventing the transmission of infections in hospitals. For instance, SwipeSense has developed a wearable device that monitors hand hygiene compliance in real time and provides feedback to healthcare workers, encouraging adherence to hand hygiene protocols.

Moreover, startups are innovating in the field of antimicrobial coatings and materials designed to inhibit the growth of pathogens on surfaces commonly found in healthcare settings. Companies such as Parx Materials are developing antimicrobial additives that can be integrated into various materials, such as plastics and textiles, to create self-sanitizing surfaces. These innovative materials have the potential to reduce the transmission of pathogens and prevent the spread of nosocomial infections. With their agility, creativity, and focus on addressing unmet needs, startups are poised to make significant contributions to improving patient outcomes and reducing the burden of nosocomial infections worldwide.

Summary of Key Findings

  • The nosocomial infections treatment market is expanding due to the increasing incidence of hospital-acquired infections, fueled by the greater use of invasive procedures and medical devices. The aging population, more prone to infections because of weakened immune systems and chronic diseases, also drives the market growth. Additionally, heightened awareness and stringent infection control regulations are prompting more investments in infection prevention. The expanding healthcare infrastructure in emerging economies further amplifies the demand for effective nosocomial infection treatments.
  • Market segmented by type of infection, treatment type, end-user, and region.
  • Urinary Tract Infections (UTIs) are the leading segment by type of infection and hold a substantial share due to the high prevalence of catheter use in hospitals, which can introduce bacteria into the urinary tract.
  • Antibiotics boast the dominating position in the nosocomial infection treatment industry, holding a massive share in 2023 due to their widespread use as the first line of defense against bacterial infections, which are the most common type of nosocomial infections.
  • North America is leading market growth; the market is highly competitive with key players including 3M Company, Abbott Laboratories, Advanced Sterilization Products Services Inc. (ASP), Becton, Dickinson and Company (BD), Belimed AG, BioMérieux SA, Cantel Medical Corp., Getinge Group, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Roche Diagnostics Corporation, Stryker Corporation, Thermo Fisher Scientific Inc., Steris Corporation, Zimmer Biomet Holdings, Inc., Ansell Limited, Molnlycke Health Care AB, and Cantel Medical Corp.

Future Outlook

  • Positive outlook for the global nosocomial infection treatment market with significant growth potential in the Asia Pacific region.
  • One of the main factors promoting the market’s expansion is the increasing incidence of hospital-acquired infections, fueled by the greater use of invasive procedures and medical devices. Additionally, heightened awareness and stringent infection control regulations are prompting more investments in infection prevention.
  • During the forecast period, the impact of antimicrobial resistance and high treatment costs is expected to act as significant factors restraining the growth of the nosocomial infection treatment market
  • To stay competitive, key firms in the nosocomial infection treatment market should prioritize investing in R&D for broad-spectrum and targeted therapies and enhancing their product portfolios with preventative and diagnostic tools.

How CXOs Can Benefit from the Credence Research Nosocomial Infection Treatment Market Report

The Credence Research nosocomial infection treatment market Report provides CXOs with a comprehensive overview of the market, including:

  • Market size and growth forecast:The report provides detailed estimates of the global nosocomial infection treatment market size, segmented by type of infection, treatment type, end-user, and region. It also includes forecasts for the market through 2032 based on key trends and drivers.
  • Market segmentation:The report segments the nosocomial infection treatment market by type of infection, treatment type, end-user, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
  • Competitive Landscape:The report profiles the key players in the nosocomial infection treatment market and provides insights into their strategies, product offerings, and financial performance. This information can help CXOs to identify and assess their competition.
  • Key trends and drivers:The report identifies and analyses the key trends and drivers shaping the nosocomial infection treatment market. This information can help CXOs make informed decisions about their investments and strategies.

CXOs can use the insights from the Credence Research Nosocomial Infection Treatment Market Report to:

  • Identify growth opportunities: The report can help CXOs identify new growth opportunities in the nosocomial infection treatment market. For example, the report identifies the rising demand for effective treatments in emerging economies with growing healthcare infrastructure.
  • Make informed investment decisions:The report can help CXOs make informed investment decisions about the nosocomial infection treatment industry. For example, it provides insights into the key factors to consider when evaluating and selecting nosocomial infection treatment providers.
  • Develop competitive strategies:The report can help CXOs develop competitive strategies for their Nosocomial Infection Treatment businesses. For example, the report identifies the key strategies that nosocomial infection treatment providers are using to differentiate themselves from their competitors.
  • Track market developments:The report can help CXOs monitor market developments and stay ahead of the curve. For example, it provides insights into the latest trends and innovations in the nosocomial infection treatment market.

Overall, the Credence Research Nosocomial Infection Treatment Market Report is a valuable resource for CXOs who are looking to gain a deeper understanding of the market and identify opportunities for growth.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segmentation

  • By Type of infection

    • Urinary Tract Infections (UTIs)
    • Surgical Site Infections (SSIs)
    • Pneumonia
    • Bloodstream Infections
    • Gastrointestinal Infections
    • Skin and Soft Tissue Infections

  • By Treatment Type

    • Antibiotics
    • Antifungal Agents
    • Antiviral Drugs
    • Surgical Interventions
    • Supportive Care

  • By End User

    • Hospitals
    • Long-Term Care Facilities
    • Ambulatory Surgical Centers
    • Clinics and Outpatient Settings
    • Home Healthcare

  • By Region

    • North Americas
      • US
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of the Middle East and Africa

Adjacent Markets

In the nosocomial infection treatment market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for nosocomial infection treatment market –

                                                        Adjacent Markets
Hospital-acquired infection (HAI) prevention market Surgical instruments market Disinfectants market
Surgical Site Infection Control Market Clostridium difficile infection (CDI) treatment market Healthcare-associated infection (HAI) market
Wound care management market Ventilator-associated pneumonia (VAP) treatment market Healthcare cleaning services market

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

 

2. Executive Summary

2.1. Market Snapshot: Global Nosocomial Infection Treatment Market

2.1.1. Global Nosocomial Infection Treatment Market, By Type of Infection

2.1.2. Global Nosocomial Infection Treatment Market, By Treatment Type

2.1.3. Global Nosocomial Infection Treatment Market, By End-User

2.1.4. Global Nosocomial Infection Treatment Market, By Region

2.2. Insights from Primary Respondents

 

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Nosocomial Infection Treatment Market Value, 2019-2032, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Nosocomial Infection Treatment Market Drivers

3.2.2. Nosocomial Infection Treatment Market Restraints

3.2.3. Nosocomial Infection Treatment Market Opportunities

3.2.4. Major Nosocomial Infection Treatment Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Type of Infection

3.5.2. Treatment Type

3.5.3. End-User

3.5.4. Geography

 

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2023

4.1.1. Global Nosocomial Infection Treatment Market: Company Market Share, Value 2023

4.1.2. Global Nosocomial Infection Treatment Market: Top 6 Company Market Share, Value 2023

4.1.3. Global Nosocomial Infection Treatment Market: Top 3 Company Market Share, Value 2023

4.2. Global Nosocomial Infection Treatment Market: Company Revenue Share Analysis, 2023

4.3. Company Assessment Metrics, 2023

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/ SMEs Assessment Metrics, 2023

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Nosocomial Infection Treatment Market

 

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

 

6. Market Positioning of Key Players, 2023

6.1. Company market share of key players, 2023

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

 

7. Impact Analysis of COVID 19 and Russia – Ukraine War on Nosocomial Infection Treatment Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

 

8. Global Nosocomial Infection Treatment Market, By Type of Infection

8.1. Global Nosocomial Infection Treatment Market Overview, by Type of Infection

8.1.1. Global Nosocomial Infection Treatment Market Revenue Share, By Type of Infection, 2023 Vs 2032 (in %)

8.2. Urinary Tract Infections (UTIs)

8.2.1. Global Nosocomial Infection Treatment Market, By Urinary Tract Infections (UTIs), By Region, 2019-2032 (US$ Mn)

8.2.2. Market Dynamics for Urinary Tract Infections (UTIs)

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Surgical Site Infections (SSIs)

8.3.1. Global Nosocomial Infection Treatment Market, By Surgical Site Infections (SSIs), By Region, 2019-2032 (US$ Mn)

8.3.2. Market Dynamics for Surgical Site Infections (SSIs)

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Pneumonia

8.4.1. Global Nosocomial Infection Treatment Market, By Pneumonia, By Region, 2019-2032 (US$ Mn)

8.4.2. Market Dynamics for Pneumonia

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Bloodstream Infections

8.5.1. Global Nosocomial Infection Treatment Market, By Bloodstream Infections, By Region, 2019-2032 (US$ Mn)

8.5.2. Market Dynamics for Bloodstream Infections

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Gastrointestinal Infections

8.6.1. Global Nosocomial Infection Treatment Market, By Gastrointestinal Infections, By Region, 2019-2032 (US$ Mn)

8.6.2. Market Dynamics for Gastrointestinal Infections

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

8.7. Skin and Soft Tissue Infections

8.7.1. Global Nosocomial Infection Treatment Market, By Skin and Soft Tissue Infections, By Region, 2019-2032 (US$ Mn)

8.7.2. Market Dynamics for Skin and Soft Tissue Infections

8.7.2.1. Drivers

8.7.2.2. Restraints

8.7.2.3. Opportunities

8.7.2.4. Trends

 

9. Global Nosocomial Infection Treatment Market, By Treatment Type

9.1. Global Nosocomial Infection Treatment Market Overview, by Treatment Type

9.1.1. Global Nosocomial Infection Treatment Market Revenue Share, By Treatment Type, 2023 Vs 2032 (in %)

9.2. Antibiotics

9.2.1. Global Nosocomial Infection Treatment Market, By Antibiotics, By Region, 2019-2032 (US$ Mn)

9.2.2. Market Dynamics for Antibiotics

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Antifungal Agents

9.3.1. Global Nosocomial Infection Treatment Market, By Antifungal Agents, By Region, 2019-2032 (US$ Mn)

9.3.2. Market Dynamics for Antifungal Agents

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Antiviral Drugs

9.4.1. Global Nosocomial Infection Treatment Market, By Antiviral Drugs, By Region, 2019-2032 (US$ Mn)

9.4.2. Market Dynamics for Antiviral Drugs

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Surgical Interventions

9.5.1. Global Nosocomial Infection Treatment Market, By Surgical Interventions, By Region, 2019-2032 (US$ Mn)

9.5.2. Market Dynamics for Surgical Interventions

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

9.6. Supportive Care

9.6.1. Global Nosocomial Infection Treatment Market, By Supportive Care, By Region, 2019-2032 (US$ Mn)

9.6.2. Market Dynamics for Supportive Care

9.6.2.1. Drivers

9.6.2.2. Restraints

9.6.2.3. Opportunities

9.6.2.4. Trends

 

10. Global Nosocomial Infection Treatment Market, By End-User

10.1. Global Nosocomial Infection Treatment Market Overview, by End-User

10.1.1. Global Nosocomial Infection Treatment Market Revenue Share, By End-User, 2023 Vs 2032 (in %)

10.2. Hospitals

10.2.1. Global Nosocomial Infection Treatment Market, By Hospitals, By Region, 2019-2032 (US$ Mn)

10.2.2. Market Dynamics for Hospitals

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Long-Term Care Facilities

10.3.1. Global Nosocomial Infection Treatment Market, By Long-Term Care Facilities, By Region, 2019-2032 (US$ Mn)

10.3.2. Market Dynamics for Long-Term Care Facilities

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Ambulatory Surgical Centers

10.4.1. Global Nosocomial Infection Treatment Market, By Ambulatory Surgical Centers, By Region, 2019-2032 (US$ Mn)

10.4.2. Market Dynamics for Ambulatory Surgical Centers

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

10.5. Clinics and Outpatient Settings

10.5.1. Global Nosocomial Infection Treatment Market, By Clinics and Outpatient Settings, By Region, 2019-2032 (US$ Mn)

10.5.2. Market Dynamics for Clinics and Outpatient Settings

10.5.2.1. Drivers

10.5.2.2. Restraints

10.5.2.3. Opportunities

10.5.2.4. Trends

10.6. Home Healthcare

10.6.1. Global Nosocomial Infection Treatment Market, By Home Healthcare, By Region, 2019-2032 (US$ Mn)

10.6.2. Market Dynamics for Home Healthcare

10.6.2.1. Drivers

10.6.2.2. Restraints

10.6.2.3. Opportunities

10.6.2.4. Trends

 

11. Global Nosocomial Infection Treatment Market, By Region

11.1. Global Nosocomial Infection Treatment Market Overview, by Region

11.1.1. Global Nosocomial Infection Treatment Market, By Region, 2023 vs 2032 (in%)

11.2. Type of Infection

11.2.1. Global Nosocomial Infection Treatment Market, By Type of Infection, 2019-2032 (US$ Mn)

11.3. Treatment Type

11.3.1. Global Nosocomial Infection Treatment Market, By Treatment Type, 2019-2032 (US$ Mn)

11.4. End-User

11.4.1. Global Nosocomial Infection Treatment Market, By End-User, 2019-2032 (US$ Mn)

 

12. North America Nosocomial Infection Treatment Market Analysis

12.1. Overview

12.1.1. Market Dynamics for North America

12.1.1.1. Drivers

12.1.1.2. Restraints

12.1.1.3. Opportunities

12.1.1.4. Trends

12.2. North America Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

12.2.1. Overview

12.2.2. SRC Analysis

12.3. North America Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

12.3.1. Overview

12.3.2. SRC Analysis

12.4. North America Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

12.4.1. Overview

12.4.2. SRC Analysis

12.5. North America Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

12.5.1. North America Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

12.5.2. U.S.

12.5.3. Canada

12.5.4. Mexico

 

13. Europe Nosocomial Infection Treatment Market Analysis

13.1. Overview

13.1.1. Market Dynamics for Europe

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. Europe Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. Europe Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. Europe Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. Europe Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

13.5.1. Europe Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

13.5.2. Germany

13.5.3. French

13.5.4. UK

13.5.5. Italy

13.5.6. Spain

13.5.7. Benelux

13.5.8. Russia

13.5.9. Rest of Europe

 

14. Asia Pacific Nosocomial Infection Treatment Market Analysis

14.1. Overview

14.1.1. Market Dynamics for Asia Pacific

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Asia Pacific Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Asia Pacific Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Asia Pacific Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Asia Pacific Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

14.5.1. Asia Pacific Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

14.5.2. China

14.5.3. Japan

14.5.4. India

14.5.5. South Korea

14.5.6. South East Asia

14.5.7. Rest of Asia Pacific

 

15. Latin America Nosocomial Infection Treatment Market Analysis

15.1. Overview

15.1.1. Market Dynamics for Latin America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Latin America Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Latin America Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Latin America Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Latin America Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

15.5.1. Latin America Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

15.5.2. Brazil

15.5.3. Argentina

15.5.4. Rest of Latin America

 

16. Middle East Nosocomial Infection Treatment Market Analysis

16.1. Overview

16.1.1. Market Dynamics for Middle East

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Middle East Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Middle East Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Middle East Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Middle East Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

16.5.1. Middle East Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

16.5.2. UAE

16.5.3. Saudi Arabia

16.5.4. Rest of Middle East

 

17. Africa Nosocomial Infection Treatment Market Analysis

17.1. Overview

17.1.1. Market Dynamics for Africa

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Africa Nosocomial Infection Treatment Market, by Type of Infection, 2019-2032(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Africa Nosocomial Infection Treatment Market, by Treatment Type, 2019-2032(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Africa Nosocomial Infection Treatment Market, by End-User, 2019-2032(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Africa Nosocomial Infection Treatment Market, by Country, 2019-2032 (US$ Mn)

17.5.1. Middle East Nosocomial Infection Treatment Market, by Country, 2023 Vs 2032 (in%)

17.5.2. South Africa

17.5.3. Egypt

17.5.4. Rest of Africa

 

18. Company Profiles

18.1. 3M Company

18.1.1. Company Overview

18.1.2. Products/Services Portfolio

18.1.3. Geographical Presence

18.1.4. SWOT Analysis

18.1.5. Financial Summary

18.1.5.1. Market Revenue and Net Profit (2019-2023)

18.1.5.2. Business Segment Revenue Analysis

18.1.5.3. Geographical Revenue Analysis

18.2. Abbott Laboratories

18.3. Advanced Sterilization Products Services Inc. (ASP)

18.4. Becton, Dickinson and Company (BD)

18.5. Belimed AG

18.6. BioMérieux SA

18.7. Cantel Medical Corp.

18.8. Getinge Group

18.9. Johnson & Johnson

18.10. Merck & Co., Inc.

18.11. Pfizer Inc.

18.12. Roche Diagnostics Corporation

18.13. Stryker Corporation

18.14. Thermo Fisher Scientific Inc.

18.15. Steris Corporation

18.16. Zimmer Biomet Holdings, Inc.

18.17. Ansell Limited

18.18. Molnlycke Health Care AB

18.19. Cantel Medical Corp

 

19. Research Methodology

19.1. Research Methodology

19.2. Phase I – Secondary Research

19.3. Phase II – Data Modelling

19.3.1. Company Share Analysis Model

19.3.2. Revenue Based Modelling

19.4. Phase III – Primary Research

19.5. Research Limitations

19.5.1. Assumptions

List of Figures

FIG. 1 Global Nosocomial Infection Treatment Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom up Approach

FIG. 3 Global Nosocomial Infection Treatment Market Segmentation

FIG. 4 Global Nosocomial Infection Treatment Market, by Type of Infection, 2023 (US$ Mn)

FIG. 5 Global Nosocomial Infection Treatment Market, by Treatment Type, 2023 (US$ Mn)

FIG. 6 Global Nosocomial Infection Treatment Market, by End-User, 2023 (US$ Mn)

FIG. 7 Global Nosocomial Infection Treatment Market, by Geography, 2023 (US$ Mn)

FIG. 8 Attractive Investment Proposition, by Type of Infection, 2023

FIG. 9 Attractive Investment Proposition, by Treatment Type, 2023

FIG. 10 Attractive Investment Proposition, by End-User, 2023

FIG. 11 Attractive Investment Proposition, by Geography, 2023

FIG. 12 Global Market Share Analysis of Key Nosocomial Infection Treatment Market Manufacturers, 2023

FIG. 13 Global Market Positioning of Key Nosocomial Infection Treatment Market Manufacturers, 2023

FIG. 14 Global Nosocomial Infection Treatment Market Value Contribution, By Type of Infection, 2023 & 2032 (Value %)

FIG. 15 Global Nosocomial Infection Treatment Market, by Urinary Tract Infections (UTIs), Value, 2019-2032 (US$ Mn)

FIG. 16 Global Nosocomial Infection Treatment Market, by Surgical Site Infections (SSIs), Value, 2019-2032 (US$ Mn)

FIG. 17 Global Nosocomial Infection Treatment Market, by Pneumonia, Value, 2019-2032 (US$ Mn)

FIG. 18 Global Nosocomial Infection Treatment Market, by Bloodstream Infections, Value, 2019-2032 (US$ Mn)

FIG. 19 Global Nosocomial Infection Treatment Market, by Gastrointestinal Infections, Value, 2019-2032 (US$ Mn)

FIG. 20 Global Nosocomial Infection Treatment Market, by Skin and Soft Tissue Infections, Value, 2019-2032 (US$ Mn)

FIG. 21 Global Nosocomial Infection Treatment Market Value Contribution, By Treatment Type, 2023 & 2032 (Value %)

FIG. 22 Global Nosocomial Infection Treatment Market, by Antibiotics, Value, 2019-2032 (US$ Mn)

FIG. 23 Global Nosocomial Infection Treatment Market, by Antifungal Agents, Value, 2019-2032 (US$ Mn)

FIG. 24 Global Nosocomial Infection Treatment Market, by Antiviral Drugs, Value, 2019-2032 (US$ Mn)

FIG. 25 Global Nosocomial Infection Treatment Market, by Surgical Interventions, Value, 2019-2032 (US$ Mn)

FIG. 26 Global Nosocomial Infection Treatment Market, by Supportive Care, Value, 2019-2032 (US$ Mn)

FIG. 27 Global Nosocomial Infection Treatment Market Value Contribution, By End-User, 2023 & 2032 (Value %)

FIG. 28 Global Nosocomial Infection Treatment Market, by Hospitals, Value, 2019-2032 (US$ Mn)

FIG. 29 Global Nosocomial Infection Treatment Market, by Long-Term Care Facilities, Value, 2019-2032 (US$ Mn)

FIG. 30 Global Nosocomial Infection Treatment Market, by Ambulatory Surgical Centers, Value, 2019-2032 (US$ Mn)

FIG. 31 Global Nosocomial Infection Treatment Market, by Clinics and Outpatient Settings, Value, 2019-2032 (US$ Mn)

FIG. 32 Global Nosocomial Infection Treatment Market, by Home Healthcare, Value, 2019-2032 (US$ Mn)

FIG. 33 North America Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 34 U.S. Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 35 Canada Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 36 Mexico Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 37 Europe Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 38 Germany Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 39 France Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 40 U.K. Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 41 Italy Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 42 Spain Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 43 Benelux Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 44 Russia Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 45 Rest of Europe Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 46 Asia Pacific Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 47 China Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 48 Japan Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 49 India Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 50 South Korea Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 51 South-East Asia Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 52 Rest of Asia Pacific Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 53 Latin America Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 54 Brazil Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 55 Argentina Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 56 Rest of Latin America Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 57 Middle East Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 58 UAE Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 59 Saudi Arabia Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 60 Rest of Middle East Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 61 Africa Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 62 South Africa Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 63 Egypt Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

FIG. 64 Rest of Africa Nosocomial Infection Treatment Market, 2019-2032 (US$ Mn)

 

List of Tables

TABLE 1 Market Snapshot: Global Nosocomial Infection Treatment Market

TABLE 2 Global Nosocomial Infection Treatment Market: Market Drivers Impact Analysis

TABLE 3 Global Nosocomial Infection Treatment Market: Market Restraints Impact Analysis

TABLE 4 Global Nosocomial Infection Treatment Market, by Competitive Benchmarking, 2023

TABLE 5 Global Nosocomial Infection Treatment Market, by Geographical Presence Analysis, 2023

TABLE 6 Global Nosocomial Infection Treatment Market, by Key Strategies Analysis, 2023

TABLE 7 Global Nosocomial Infection Treatment Market, by Urinary Tract Infections (UTIs), By Region, 2019-2023 (US$ Mn)

TABLE 8 Global Nosocomial Infection Treatment Market, by Urinary Tract Infections (UTIs), By Region, 2024-2032 (US$ Mn)

TABLE 9 Global Nosocomial Infection Treatment Market, by Surgical Site Infections (SSIs), By Region, 2019-2023 (US$ Mn)

TABLE 10 Global Nosocomial Infection Treatment Market, by Surgical Site Infections (SSIs), By Region, 2024-2032 (US$ Mn)

TABLE 11 Global Nosocomial Infection Treatment Market, by Pneumonia, By Region, 2019-2023 (US$ Mn)

TABLE 12 Global Nosocomial Infection Treatment Market, by Pneumonia, By Region, 2024-2032 (US$ Mn)

TABLE 13 Global Nosocomial Infection Treatment Market, by Bloodstream Infections, By Region, 2019-2023 (US$ Mn)

TABLE 14 Global Nosocomial Infection Treatment Market, by Bloodstream Infections, By Region, 2024-2032 (US$ Mn)

TABLE 15 Global Nosocomial Infection Treatment Market, by Gastrointestinal Infections, By Region, 2019-2023 (US$ Mn)

TABLE 16 Global Nosocomial Infection Treatment Market, by Gastrointestinal Infections, By Region, 2024-2032 (US$ Mn)

TABLE 17 Global Nosocomial Infection Treatment Market, by Skin and Soft Tissue Infections, By Region, 2019-2023 (US$ Mn)

TABLE 18 Global Nosocomial Infection Treatment Market, by Skin and Soft Tissue Infections, By Region, 2024-2032 (US$ Mn)

TABLE 19 Global Nosocomial Infection Treatment Market, by Antibiotics, By Region, 2019-2023 (US$ Mn)

TABLE 20 Global Nosocomial Infection Treatment Market, by Antibiotics, By Region, 2024-2032 (US$ Mn)

TABLE 21 Global Nosocomial Infection Treatment Market, by Antifungal Agents, By Region, 2019-2023 (US$ Mn)

TABLE 22 Global Nosocomial Infection Treatment Market, by Antifungal Agents, By Region, 2024-2032 (US$ Mn)

TABLE 23 Global Nosocomial Infection Treatment Market, by Antiviral Drugs, By Region, 2019-2023 (US$ Mn)

TABLE 24 Global Nosocomial Infection Treatment Market, by Antiviral Drugs, By Region, 2024-2032 (US$ Mn)

TABLE 25 Global Nosocomial Infection Treatment Market, by Surgical Interventions, By Region, 2019-2023 (US$ Mn)

TABLE 26 Global Nosocomial Infection Treatment Market, by Surgical Interventions, By Region, 2024-2032 (US$ Mn)

TABLE 27 Global Nosocomial Infection Treatment Market, by Supportive Care, By Region, 2019-2023 (US$ Mn)

TABLE 28 Global Nosocomial Infection Treatment Market, by Supportive Care, By Region, 2024-2032 (US$ Mn)

TABLE 29 Global Nosocomial Infection Treatment Market, by Hospitals, By Region, 2019-2023 (US$ Mn)

TABLE 30 Global Nosocomial Infection Treatment Market, by Hospitals, By Region, 2024-2032 (US$ Mn)

TABLE 31 Global Nosocomial Infection Treatment Market, by Long-Term Care Facilities, By Region, 2019-2023 (US$ Mn)

TABLE 32 Global Nosocomial Infection Treatment Market, by Long-Term Care Facilities, By Region, 2024-2032 (US$ Mn)

TABLE 33 Global Nosocomial Infection Treatment Market, by Ambulatory Surgical Centers, By Region, 2019-2023 (US$ Mn)

TABLE 34 Global Nosocomial Infection Treatment Market, by Ambulatory Surgical Centers, By Region, 2024-2032 (US$ Mn)

TABLE 35 Global Nosocomial Infection Treatment Market, by Clinics and Outpatient Settings, By Region, 2019-2023 (US$ Mn)

TABLE 36 Global Nosocomial Infection Treatment Market, by Clinics and Outpatient Settings, By Region, 2024-2032 (US$ Mn)

TABLE 37 Global Nosocomial Infection Treatment Market, by Home Healthcare, By Region, 2019-2023 (US$ Mn)

TABLE 38 Global Nosocomial Infection Treatment Market, by Home Healthcare, By Region, 2024-2032 (US$ Mn)

TABLE 39 Global Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 40 Global Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 41 Global Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 42 Global Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 43 Global Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 44 Global Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 45 Global Nosocomial Infection Treatment Market, by Region, 2019-2023 (US$ Mn)

TABLE 46 Global Nosocomial Infection Treatment Market, by Region, 2024-2032 (US$ Mn)

TABLE 47 North America Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 48 North America Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 49 North America Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 50 North America Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 51 North America Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 52 North America Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 53 North America Nosocomial Infection Treatment Market, by Country, 2019-2023 (US$ Mn)

TABLE 54 North America Nosocomial Infection Treatment Market, by Country, 2024-2032 (US$ Mn)

TABLE 55 United States Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 56 United States Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 57 United States Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 58 United States Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 59 United States Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 60 United States Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 61 Canada Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 62 Canada Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 63 Canada Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 64 Canada Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 65 Canada Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 66 Canada Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 67 Mexico Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 68 Mexico Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 69 Mexico Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 70 Mexico Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 71 Mexico Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 72 Mexico Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 73 Europe Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 74 Europe Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 75 Europe Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 76 Europe Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 77 Europe Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 78 Europe Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 79 Europe Nosocomial Infection Treatment Market, by Country, 2019-2023 (US$ Mn)

TABLE 80 Europe Nosocomial Infection Treatment Market, by Country, 2024-2032 (US$ Mn)

TABLE 81 Germany Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 82 Germany Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 83 Germany Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 84 Germany Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 85 Germany Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 86 Germany Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 87 France Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 88 France Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 89 France Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 90 France Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 91 France Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 92 France Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 93 United Kingdom Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 94 United Kingdom Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 95 United Kingdom Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 96 United Kingdom Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 97 United Kingdom Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 98 United Kingdom Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 99 Italy Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 100 Italy Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 101 Italy Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 102 Italy Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 103 Italy Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 104 Italy Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 105 Spain Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 106 Spain Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 107 Spain Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 108 Spain Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 109 Spain Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 110 Spain Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 111 Benelux Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 112 Benelux Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 113 Benelux Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 114 Benelux Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 115 Benelux Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 116 Benelux Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 117 Russia Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 118 Russia Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 119 Russia Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 120 Russia Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 121 Russia Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 122 Russia Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 123 Rest of Europe Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 124 Rest of Europe Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 125 Rest of Europe Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 126 Rest of Europe Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 127 Rest of Europe Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 128 Rest of Europe Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 129 Asia Pacific Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 130 Asia Pacific Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 131 Asia Pacific Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 132 Asia Pacific Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 133 Asia Pacific Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 134 Asia Pacific Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 135 China Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 136 China Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 137 China Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 138 China Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 139 China Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 140 China Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 141 Japan Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 142 Japan Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 143 Japan Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 144 Japan Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 145 Japan Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 146 Japan Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 147 India Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 148 India Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 149 India Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 150 India Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 151 India Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 152 India Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 153 South Korea Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 154 South Korea Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 155 South Korea Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 156 South Korea Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 157 South Korea Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 158 South Korea Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 159 South-East Asia Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 160 South-East Asia Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 161 South-East Asia Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 162 South-East Asia Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 163 South-East Asia Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 164 South-East Asia Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 165 Rest of Asia Pacific Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 166 Rest of Asia Pacific Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 167 Rest of Asia Pacific Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 168 Rest of Asia Pacific Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 169 Rest of Asia Pacific Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 170 Rest of Asia Pacific Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 171 Latin America Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 172 Latin America Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 173 Latin America Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 174 Latin America Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 175 Latin America Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 176 Latin America Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 177 Brazil Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 178 Brazil Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 179 Brazil Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 180 Brazil Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 181 Brazil Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 182 Brazil Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 183 Argentina Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 184 Argentina Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 185 Argentina Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 186 Argentina Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 187 Argentina Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 188 Argentina Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 189 Rest of Latin America Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 190 Rest of Latin America Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 191 Rest of Latin America Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 192 Rest of Latin America Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 193 Rest of Latin America Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 194 Rest of Latin America Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 195 Middle East Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 196 Middle East Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 197 Middle East Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 198 Middle East Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 199 Middle East Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 200 Middle East Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 201 UAE Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 202 UAE Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 203 UAE Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 204 UAE Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 205 UAE Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 206 UAE Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 207 Saudi Arabia Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 208 Saudi Arabia Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 209 Saudi Arabia Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 210 Saudi Arabia Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 211 Saudi Arabia Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 212 Saudi Arabia Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 213 Rest of Middle East Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 214 Rest of Middle East Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 215 Rest of Middle East Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 216 Rest of Middle East Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 217 Rest of Middle East Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 218 Rest of Middle East Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 219 Africa Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 220 Africa Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 221 Africa Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 222 Africa Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 223 Africa Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 224 Africa Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 225 South Africa Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 226 South Africa Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 227 South Africa Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 228 South Africa Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 229 South Africa Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 230 South Africa Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 231 Egypt Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 232 Egypt Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 233 Egypt Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 234 Egypt Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 235 Egypt Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 236 Egypt Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

TABLE 237 Rest of Africa Nosocomial Infection Treatment Market, by Type of Infection, 2019-2023 (US$ Mn)

TABLE 238 Rest of Africa Nosocomial Infection Treatment Market, by Type of Infection, 2024-2032 (US$ Mn)

TABLE 239 Rest of Africa Nosocomial Infection Treatment Market, by Treatment Type, 2019-2023 (US$ Mn)

TABLE 240 Rest of Africa Nosocomial Infection Treatment Market, by Treatment Type, 2024-2032 (US$ Mn)

TABLE 241 Rest of Africa Nosocomial Infection Treatment Market, by End-User, 2019-2023 (US$ Mn)

TABLE 242 Rest of Africa Nosocomial Infection Treatment Market, by End-User, 2024-2032 (US$ Mn)

Frequently Asked Questions:

What is the current size of the global nosocomial infection treatment market?

The global nosocomial infection treatment market was valued at USD 30154.56 Million in 2023.

What is the expected growth rate of the nosocomial infection treatment market between 2024 and 2032?

The nosocomial infection treatment market is expected to grow at a CAGR of 1.90% between 2024 and 2032, reaching USD 35720.76 million in 2032.

Which segment is leading the market share in terms of type of infection?

Urinary Tract Infections (UTIs) are the leading segment by type of infection and hold a substantial share in 2023.

Which segment is leading the market share in terms of Treatment Type?

The antibiotics segment held the major share in value in 2023.

Which segment is expected to post the highest CAGR during the forecast period in terms of End Users?

Long-term care Facilities are expected to grow at the highest rate during the forecasted period. The increasing elderly population globally, who are more susceptible to infections and often require extended care, fuels growth in These Facilities.

Which region is dominating the nosocomial infection treatment market share?

North America is dominating the nosocomial infection treatment market share, with the highest share in 2023.

Who are the major players in the global nosocomial infection treatment market?

3M Company, Abbott Laboratories, Advanced Sterilization Products Services Inc. (ASP), Becton, Dickinson and Company (BD), Belimed AG, BioMérieux SA, Cantel Medical Corp., Getinge Group, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Roche Diagnostics Corporation, Stryker Corporation, Thermo Fisher Scientific Inc., Steris Corporation, Zimmer Biomet Holdings, Inc., Ansell Limited, Molnlycke Health Care AB, and Cantel Medical Corp. are the prominent players in the nosocomial infection treatment market.

What are the major market drivers of the global nosocomial infection treatment market?

The nosocomial infection treatment market is expanding due to the increasing incidence of hospital-acquired infections fueled by the greater use of invasive procedures and medical devices. The aging population, more prone to infections because of weakened immune systems and chronic diseases, also drives the market growth. Additionally, heightened awareness and stringent infection control regulations are prompting more investments in infection prevention. The expanding healthcare infrastructure in emerging economies further amplifies the demand for effective nosocomial infection treatments.

What is the major market restraint of the nosocomial infection treatment market?

The combined impact of antimicrobial resistance and high treatment costs significantly restrains the growth of the nosocomial infections treatment market. Pathogens are increasingly resistant to standard treatments, leading to longer hospital stays, higher medical costs, and increased mortality. Developing new, effective drugs is a lengthy and expensive process. Additionally, the high costs of advanced diagnostic tools and therapeutic interventions limit their accessibility, particularly in low- and middle-income countries.

What are the major market opportunities of the global nosocomial infection treatment market?

Technological advancements in healthcare are creating substantial opportunities for the growth of the nosocomial infection treatment market. Innovations in diagnostic tools and therapeutic interventions are revolutionizing infection control and treatment, leading to more efficient and effective healthcare solutions. Rapid diagnostic technologies, such as PCR and next-generation sequencing, enable quicker and more accurate pathogen identification. This allows for timely and targeted treatments, reducing infection spread and improving patient outcomes. These advancements are transforming healthcare systems, leading to better patient care and robust healthcare infrastructures in the future.

Related Reports

United Kingdom Diabetes Care Devices Market

Published:
Report ID: 64238

Botulinum Toxin Market

Published:
Report ID: 3442

Psoriasis Treatment Market

Published:
Report ID: 8131

Malaysia Diabetes Care Devices Market

Published:
Report ID: 63945

Antihistamine Drugs Market

Published:
Report ID: 63917

Astaxanthin Market

Published:
Report ID: 63913

Anti-Venom Market

Published:
Report ID: 63874

Treatment Resistant Hypertension Management Market

Published:
Report ID: 63658

Urinary Antibacterial and Antiseptic Pharmaceuticals Market

Published:
Report ID: 63705

Russia Chronic Pain Market

Published:
Report ID: 63723

Uncomplicated Urinary Tract Infection Treatment Market

Published:
Report ID: 63668

Ulcerated Necrobiosis Lipoidica Management Market

Published:
Report ID: 63662

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$4699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$5699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$7699

Request Free Sample

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207

support

24/7 Research Support

sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

Get Methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
Request Free Sample